Table 1

Patients’ baseline characteristics

Intervention group (n=175)Control group (n=182)
Age, years, mean (SD)64.8 (8.7)65.8 (8.8)
Sex, male, % (n)52.6 (92)60.4 (110)
Recruiting healthcare provider
 Primary care, % (n)54.9 (96)63.7 (116)
 Hospital care, % (n)45.1 (79)36.3 (66)
FEV1/FVC ratio, mean (SD)48.5 (12.8)52.1 (11.8)
FEV1, % predicted, mean (SD)56.6 (17.8)62.3 (19.8)
GOLD stage, % (n)
 1 (FEV1 >80% predicted)8.6 (15)17.0 (31)
 2 (FEV1 50–80% predicted)48.6 (85)46.7 (85)
 3 (FEV1 30–50% predicted)30.9 (54)24.2 (44)
 4 (FEV1 <30% predicted)5.1 (9)2.7 (5)
 Missing6.9 (12)9.3 (17)
Diagnosed with COPD since, % (n)
 1–3 year(s)33.1 (58)26.4 (48)
 >3 years62.3 (109)67.0 (122)
 Unknown4.6 (8)6.6 (12)
Number of exacerbations in last year, % (n)
 044.0 (77)49.5 (90)
 126.3 (46)24.7 (45)
 212.0 (21)10.4 (19)
 >213.7 (24)7.7 (14)
 Missing4.0 (7)7.7 (14)
Smoking status, % (n)
 Current smoker32.6 (57)24.7 (45)
 Ex-smoker60.0 (105)60.4 (110)
 Never smoked5.1 (9)4.4 (8)
 Missing2.3 (4)10.4 (19)
Pack-years smoking, mean (SD)33.2 (28.3)30.8 (23.7)
Baseline SGRQ, mean (SD)
 Symptoms49.9 (22.2)44.2 (25.5)
 Activity44.6 (23.8)41.4 (24.3)
 Impact24.6 (14.7)22.8 (15.1)
 Total39.7 (17.8)36.2 (19.3)
  • COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SGRQ, St. George's Respiratory Questionnaire.